Skip to main content

Home/ Vitamin D/ Group items tagged 2010

Rss Feed Group items tagged

Matti Narkia

Lonkkamurtumapotilaiden kuolleisuus vähennettävissä - Apteekkari.fi - 0 views

  •  
    "04.01.2010 15:00 D-vitamiini ja kalisum vähentävät lonkkamurtumapotilaiden kuolleisuutta, osoittaa tuore suomalaistutkimus. Lonkkamurtuma on vaikein osteoporoosin eli luukadon heikentämän luun murtuma, ja siihen liittyy huomattava ylikuolleisuus ja toimintakyvyn heikkeneminen. Drugs Aging -lehdessä (2009;26:409-421) hiljattain julkaistun suomalaistutkimuksen mukaan kalsiumin ja D-vitamiinin samanaikaisella käytöllä lonkkamurtumapotilaiden kuolleisuutta voitaisiin kuitenkin vähentää. Dosentti Peter Lüthje työryhmineen tutki Päijät-Hämeen keskussairaalan ja Kuusankosken aluesairaalan vastuualueella vuosina 2003-2004 hoidettujen lonkkamurtumapotilaiden elimistön D-vitamiinipitoisuuksia ja D-vitamiinin käytön yhteyttä murtuman jälkeiseen selviytymiseen. Tutkimusaineisto koostui 221 lonkkamurtumapotilaasta. Naisten keski-ikä oli 81 vuotta ja miesten 73 vuotta. Potilaiden selviytymistä seurattiin murtuman jälkeen 37-52 kuukautta. 28 kuukauden seurannan kohdalla 221 tutkimukseen kuuluvasta potilaasta elossa oli 137 potilasta (62 %). Tilastoanalyysissa tärkeimmäksi lonkkamurtumasta selviytymistä selittäväksi tekijäksi osoittautui D-vitamiinin ja kalsiumin käyttö (kalsium- ja D-vitamiinilääkitys). Toiseksi tärkein selittävä tekijä oli osteoporoosilääkitys"
Matti Narkia

Welcome to to VITamin D and omegA-3 triaL (VITAL) Web site - 0 views

  •  
    What is VITAL? The VITamin D and OmegA-3 TriaL (VITAL) is a research study in 20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin D (about 2000 IU) or fish oil (about 1 gram of omega-3 fatty acids) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. Recruitment for the study will begin in January 2010.
Matti Narkia

Low vitamin D serum level is related to severe fibrosis and low responsiveness to IFN-b... - 0 views

  •  
    Low vitamin D serum level is related to severe fibrosis and low responsiveness to IFN-based therapy in genotype 1 chronic hepatitis C Salvatore Petta et al. Hepatology, Volume 9999 Issue 999A, Page NA. Published Online: 4 Dec 2009 DOI: 10.1002/hep.23489 Conclusions: G1 CHC patients had low 25(OH)D serum levels, possibly due to reduced CYP27A1 expression. Low vitamin D is linked to severe fibrosis and low SVR on IFN-based therapy. (HEPATOLOGY 2010.)
Matti Narkia

A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in brea... - 0 views

  •  
    A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases. Amir E, Simmons CE, Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M. Cancer. 2009 Nov 13. [Epub ahead of print] PMID: 19918922 DOI: 10.1002/cncr.24749 METHODS: Patients with bone metastases treated with bisphosphonates were enrolled into this single-arm phase 2 study. Patients received 10,000 IU of vitamin D3 and 1000 mg of calcium supplementation each day for 4 months. The effect of this treatment on palliation, bone resorption markers, calcium metabolism, and toxicity were evaluated at baseline and monthly thereafter. CONCLUSIONS: Daily doses of 10,000 IU vitamin D3 for 4 months appear safe in patients without comorbid conditions causing hypersensitivity to vitamin D. Treatment reduced inappropriately elevated parathyroid hormone levels, presumably caused by long-term bisphosphonate use. There did not appear to be a significant palliative benefit nor any significant change in bone resorption. Cancer 2010. © 2009 American Cancer Society.
Matti Narkia

Massive vitamin-D/omega-3 trial in the works - theheart.org - 0 views

  •  
    "June 29, 2009 | Shelley Wood Boston, MA - A massive, National Institutes of Health-sponsored study looking at whether vitamin-D and/or omega-3 fatty-acid supplementation can reduce the risk of developing heart disease, stroke, or cancer will get under way in January 2010, according to a website for the study. Drs JoAnn Manson and Julie Buring (Harvard Medical School/ Brigham and Women's Hospital, Boston, MA) will head up the Vitamin D and Omega-3 Trial (VITAL). The study is aiming to enroll 20 000 men and women, one-quarter of whom will be black. According to a Brigham and Women's Hospital press release, the study is intentionally aiming to illuminate a potential racial and ethnic disparity hypothesized to be linked to vitamin D [1]. "African Americans have a higher risk of vitamin-D deficiency as well as a greater frequency of diabetes, hypertension, and certain types of cancer," a press release notes. For VITAL, women need to be over age 65 to enter the study; men need to be over age 60. Study participants will be randomized to one of four groups: daily vitamin D (2000 IU) and fish oil (1 g); daily vitamin D and fish-oil placebo; daily vitamin-D placebo and fish oil; or daily vitamin-D placebo and fish-oil placebo. The trial will run for five years and is expected to cost US $20 million."
Matti Narkia

Mitkä lääkkeet estävät D-vitamiinia? | Tohtori Tolonen - 1 views

  •  
    "Tällä sivulla mainitut lääkkeet voivat estää auringon valon UVB-säteitä muodostamasta ihossa D-vitamiinia ja D-vitamiinin imeytymistä ravinnosta ja ravintolisistä. Lääkkeiden käyttäjän D-vitamiinin pitoisuus seerumissa (S-D-25) voi olla pienempi kuin mikä on terveyden kannalta ihanteellista (75-250 nmol/l). Suomalaisten S-D-25 on muutoinkin keskimäärin vain noin 40 nmol/l, elleivät he käytä D-vitamiinilisiä. Lääkkeen säännöllinen käyttö voi siten vaatia tavallistakin suurempaa D-vitamiinin saantia ravintolisän muodossa. Orlistaatti (kauppanimiä Alli ja Xenical, laihdutuslääkkeitä, estävät rasvojen ja rasvaliukoisten vitamiinien imeytymistä suolesta vereen), barbituraatit (unilääkkeet), karbamatsepiini (epilepsialääke), kolestyramiini, simetidiini (Tagamet), kolestipoli, kortikosteroidit (kortisonit), famotidiini (käytetään liikahappoisuuteen), fosfenytoiini (epilepsialääke), isoniatsidi (tuberkuloosilääke, nitsatidiini (mahahaavalääke), fenobarbitaali (epilepsia- ja unilääke), fenytoiini (epilepsialääke), ranitidiini (mahahaavalääke), rifampiini eli fluvastatiini ja valproaatti (epilepsialääke)."
Matti Narkia

What To Do If You Contract Influenza: Including H1N1 (Swine) Flu or the Common Cold - L... - 0 views

  •  
    "With daily news reports warning of a swine flu pandemic, members have besieged our health advisors with questions about what they should do to protect themselves against the H1N1 (swine flu) virus. The good news is that Life Extension® members obtain a considerable amount of immune support via the supplements they already use, especially those taking high-dose vitamin D. An important question, however, is what one should do if they develop symptoms of a viral infection? As the days grow colder, the risks of contracting common flu and cold viruses increase. Each year, flu virus infections kill around 36,000 Americans and cause miseries for millions.1 An outbreak of the swine flu virus is expected this winter. While certain supplements (and drugs) purport to shorten the duration of a viral infection, most of them fail to provide significant relief. Over the past 28 years, Life Extension® personnel have experimented with various nutrients, hormones, and drugs in order to minimize the impact of the common cold and typical flu viruses. In this article, I will reveal what has worked for me personally to ward off common cold/flu viruses and what has been validated in the scientific literature to be effective. I will also elaborate on some aggressive prescription drug strategies to consider in the event that you contract a severe form of swine flu or other type of influenza."
1 - 7 of 7
Showing 20 items per page